Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to eight (8) new employees to purchase 60,400 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule...
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance -- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) -- ...
Advantage Solutions Reports Second Quarter 2025 Results Strong profitability growth in Experiential and Retailer Services Advancing transformation initiatives to accelerate AI enablement and improved business insights Expecting improved financial performance and cash generation in the second half of the year Reaffirming 2025 guidance ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” “Advantage Solutions,” the “Company,” “we,” or “our”), a leading business solutions provider to consumer goods manufacturers and retailers, today re...
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 h...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7 DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025. A live audio webcast of the call can be accessed by visiting the investo...
Advantage Solutions to Participate in The Canaccord Annual Growth Conference on August 12, 2025 ST. LOUIS, July 30, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ GS: ADV) announced today that Dave Peacock, Chief Executive Officer, and Chris Growe, Chief Financial Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston on Aug. 12, 2025. A live fireside chat with Dave Peacock will be held at noon EDT. The listen-only webcast can be accessed from the Advantage Solutions website at . For more details, contact your Canaccord Genuity representative...
Advantage Solutions Announces Date for its Second Quarter 2025 Financial Results and Conference Call ST. LOUIS, July 25, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ GS: ADV) announced today that it will release financial results for the second quarter at 7 a.m. EDT on Aug. 7, 2025, followed by a conference call at 8:30 a.m. EDT on the same day. The conference call can be accessed live by dialing 1-800-715-9871 for U.S. callers or 1-646-307-1963 for international callers. The conference ID is 5720569. Approximately three hours after the call, a replay will be available by di...
OPKO Health to Report Second Quarter 2025 Financial Results on July 31 MIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Thursday, July 31, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on July 31 beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-re...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, July 21, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase 34,200 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5...
CORRECTION - Ad Age lists Advantage Solutions among 2025 Largest Agencies Advantage Solutions ranks No. 18 on the global list ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on July 2 by Advantage Solutions Inc. (NASDAQ: ADV), please note that Advantage’s domestic ranking should have been listed as “12th in the United States” instead of “9th in North America.” It has been removed from the subhead. The corrected release follows: Advantage Solutions (NASDAQ: ADV) ranks as the 12th largest agency company in the United States and No. 18 worldwide, a...
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress, taking place September 13–16, 2025, in Prague, Czech Republic. A...
Ad Age lists Advantage Solutions among 2025 Largest Agencies Advantage Solutions ranks No. 9 in North America and No. 18 on the global list ST. LOUIS, July 02, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) ranks as the 9th largest agency company in North America and No. 18 worldwide, according to the Ad Age Agency Report 2025. With revenue of $1.2 billion in 2024, Advantage was one of only two Midwest-based agencies in the top 25 list, which is based on worldwide revenue. “Our agency work is one of the many ways we’re shaping how people shop and building momentum in t...
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) affirmed a prior decision of the U.S. District Court for the District of Columbia (the “District Court”) in favor of the U.S. Food and Drug Admin...
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics ...
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.